Propofol infusion syndrome in children

Paediatric Anaesthesia

Volumn 8, Issue 6, 1998, Pages 491-499

  Bray, R J ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Intensive care; Lipaemia; Metabolic acidosis; Myocardial failure; Propofol; Sedation

Indexed keywords

CREATINE KINASE; LACTIC ACID; PROPOFOL;

ARTICLE; ARTIFICIAL VENTILATION; BRADYCARDIA; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTRACHEAL TUBE; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; INFANT; INTENSIVE CARE UNIT; METABOLIC ACIDOSIS; MORTALITY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RHABDOMYOLYSIS; SEDATION; SYNDROME;

ACIDOSIS; CHILD; CHILD, PRESCHOOL; FEMALE; HEART DISEASES; HUMANS; HYPNOTICS AND SEDATIVES; INFANT; INFUSIONS, INTRAVENOUS; LIPIDS; MALE; PROPOFOL; RESPIRATORY TRACT INFECTIONS; SYNDROME; TIME FACTORS;

EID: 0031785577     PISSN: 11555645     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1460-9592.1998.00282.x     Document Type: Article

References (59)

1. Parke TJ, Stevens JE, Rice ASC et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. Br Med J 1992; 305: 613-616.
2. Committee on Safety of Medicines. Serious adverse effects and fatalities in children associated with the use of propofol (Diprivan) for sedation. Curr Prob 1992; 34.
3. Rodgers EM. Diprivan intensive care sedation in children. Br J Anaesth 1991; 67: 505.
4. Edwards KG. 'Diprivan' ICU sedation in children - unlicensed use. Serious adverse events including fatalities. Letter to doctors 29th April 1992; ICI Pharmaceuticals.
5. Edwards KG, Arnold BDC. Propofol infusion in children. Br Med J 1992; 305: 952.
6. FDA's Anesthetic and Life Support Drugs Advisory Committee. ICI's Diprivan (propofol) anesthetic has no direct link to pediatric deaths in ICUs, FDA advisory committee finds; FDA asks ICI to pursue pediatric indication. FDC Reports 1992; 54: 14.
7. Brown MM, Manara AR. Audit of the use of propofol infusions for sedating children requiring positive pressure ventilation on intensive care. Br J Intens Care 1995; 5: 307.
8. Hawkins WJ, Cohen AT. Fatal myocardial failure associated with a propofol infusion in a child. Anaesthesia 1995; 50: 564.
9. Reed MD, Blumer JL. Propofol bashing: the time to stop is now! Crit Care Med 1996; 24: 175-177.
10. Reed MD, Yamashita TS, Marx CM et al. A pharmacokinetically based dosing strategy for sedation of the critically ill, mechancially ventilated pediatric patient. Crit Care Med 1996; 24: 1473-1481.
11. Pepperman ML, Macrae D. A comparison of propofol and other sedative use in paediatric intensive care in the United Kingdom. Paed Anaesth 1997; 7: 143-153.
12. Martin PH, Murthy BVS, Petros AJ. Metabolic, biochemical and haemodynamic effects of infusion of propofol for long-term sedation of children undergoing intensive care. Br J Anaesth 1997; 79: 276-279.
13. Hatch DJ. Propofol in paediatric intensive care (Editorial) Br J Anaesth 1997; 79: 274-275.
14. Barclay K, Williams AJ, Major E. Propofol infusion in children. Br Med J 1992; 304: 953.
15. Bray RJ. Fatal myocardial failure associated with a propofol infusion in a child. Anaesthesia 1995; 50: 94.
16. Notits fra Bivirkningsnænet. Propofol (Diprivan) bivirkninger. Ugeskr Læger 1990; 152/16: 1176.
17. Personal communication 1, Sundhedsstyreisen, Danish Medicines Agency, Frederikssundevej 378, 2700 Brønshøj, Denmark.
18. Bivirkningsnemnda. Bruk av propofol (Diprivan) til barn. Tidsskrift for Den Norske Lægeforen nr 12 1992; 112: 1636-1637.
19. Personal communication 2, Source confidential.
20. Personal communication 3, Source confidential.
21. Refstad S. Legens personlige ansvar. Erfaringer fra Diprivansaken. Tidsskrift for Den Norske Lægenforen nr 13 1997; 117: 1937-1939.
22. Strickland RA, Murray MJ. Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: Is there a relationship? Crit Care Med 1995; 23: 405-409.
23. Personal communication 4, Committee on Safety of Medicines, Market Towers, 1 Nine Elms Lane, London SW8 5NQ.
24. Personal communication 5, Committee on Safety of Medicines, Market Towers, 1 Nine Elms Lane, London SW8 5NQ.
25. Personal communication 6, Freedom of Information Staff, Food and Drug Administration, Rockville MD 20857, USA.
26. Personal communication 7, Centre National de Pharmacovigilance, Ministere de la Sante Publique et de l'Environnement, Cite administrative de l'Etat, Quartier Vesale, 1010, Bruxelles, Belgium.
27. Personal communication 8, Bureau of Drug Surveillance, Therapeutic Products Directorate, Address locator # 4103A, Ottawa, Ontario K1A 1B9, Canada (plus additional information, source confidential).
28. Personal communication 9, Bureau of Drug Surveillance, Therapeutic Products Directorate, Address locator # 4103A, Ottawa, Ontario K1A 1B9, Canada.
29. Cray SH, Robinson BH. Lactic acidaemia and bradyarrhythmia in a child sedated with propofol. Crit Care Med 1998 (in press).
30. Plotz FB, Waalkens HJ, Verkade HJ et al. Fatal side effects of continuous propofol infusion in children may be related to malignant hyperthermia. Anaesth Intens Care 1996; 24: 724.
31. Waalkens HJ, Plotz FB, Verkade HJ et al. Langdurige sedatie met propofol gecontraindiceerd bij kinderen. Ned Tijdschr Geneeskd 1997; 141: 440-442.
32. Personal communication 11, Division of Drug Epidemiology, Lakemedelsverket, Box 26, S-751 03, Uppsala, Sweden.
33. van Straaten EA, Hendriks JJE, Ramsey G et al. Rhabdomyolysis and pulmonary hypertension in a child, possibly due to long-term high-dose propofol infusion. Intens Care Med 1996; 22: 997.
34. Purcell-Jones G, Yates A, Baker JR et al. Comparison of the induction characteristics of thiopentone and propofol in children. Br J Anaesth 1987; 59: 1431-1436.
35. Morton NS, Wee M, Christie G et al. Propofol for induction of anaesthesia in children. Anaesthesia 1988; 43: 350-355.
36. Mirakhur RK. Induction characteristics of propofol in children: comparison with thiopentone. Anaesthesia 1988; 43: 593-598.
37. Valtonen M, Iisalo E, Kanto J. et al. Comparison between propofol and thiopentone for induction of anaesthesia in children. Anaesthesia 1988; 43: 696-699.
38. Valtonen M, Iisalo E, Kanto J et al. Propofol as an induction agent in children: pain on injection and pharmacokinetics. Acta Anaesth Scand 1989; 33: 152-155.
39. Short SM, Aun CST. Haemodynamic effects of propofol in children. Anaesthesia 1991; 46: 783-785.
40. Hannallah RS, Baker SB, Casey W et al. Effective dose and induction characteristics in unpremedicated children. Anesthesiology 1991; 74: 217-219.
41. Westrin P. The induction dose of propofol in infants 1-6 months of age and in children 10-16 years of age. Anesthesiology 1991; 74: 455-458.
42. Browne BL, Prys-Roberts C, Wolf AR. Propofol and alfentanil in children: infusion technique and dose requirement for total I.V. anaesthesia. Br J Anaesth 1992; 69: 570-576.
43. Manschot HJ, Meursing AEE, Axt P et al. Propofol requirements for induction of anesthesia in children of different age groups. Anesth Analg 1992; 75: 876-879.
44. Hiller A, Saarnivaara L. Injection pain, cardiovascular changes and recovery following induction of anaesthesia with propofol in combination with alfentanil or lignocaine in children. Acta Anaesth Scand 1992; 36: 564-568.
45. Martin TM, Nicolson SC, Bargas MS. Propofol anesthesia reduces emesis and airway obstruction in pediatric outpatients. Anesth Analg 1993; 76: 144-148.
46. Doyle E, McFadzean W, Morton NS. IV anaesthesia with propofol using a target-controlled infusion system: comparison with inhalation anaesthesia for general surgical procedures in children. Br J Anaesth 1993; 70: 542-545.
47. Aun CST, Sung RYT, O'Meara ME et al. Cardiovascular effects of IV induction in children: comparison between propofol and thiopentone. Br J Anaesth 1993; 70: 647-653.
48. Bloomfield EL, Masaryk TJ, Caplin A. et al. Intravenous sedation for MR imaging of the brain and spine in children: pentobarbital versus propofol. Radiology 1993; 186: 93-97.
49. Hiller A. Comparison of cardiovascular changes during anaesthesia and recovery from propofol-alfentanil-nitrous oxide and thiopentone-halothane-nitrous oxide anaesthesia in children undergoing otolaryngological surgery. Acta Anaesth Scand 1993; 37: 737-741.
50. Data Sheet, Diprivan, Zeneca Pharmaceuticals, Wilmslow, Cheshire. King's Court, Water Lane, SK9 5AZ, UK.
51. Gempeler F, Elston AC, Thompson SP et al. Propofol and Intralipid cause creaming of serum from critically ill patients. Anaesthesia 1994; 49: 17-20.
52. Data Sheet, Intralipid, Pharmacia & Upjohn, Milton Keynes, Bucks: Davy Avenue, Knowlhill, MK5 8PH.
53. Marinella MA. Lactic acidosis associated with propofol. Chest 1996; 109: 292.
54. El-Ebiary M, Torres A, Ramirez J. et al. Lipid deposition during the long-term infusion of propofol. Crit Care Med 1995; 23: 1928-1930.
55. ++ regulation by malignant hyperthermia-susceptible muscle membranes. Anesthesiology 1995; 82: 1274-1282.
56. McKenzie AJ, Couchman KG, Pollock N. Propofol is a 'safe' anaesthetic agent in malignant hyperthermia susceptible patients. Anaesth Intens Care 1992; 20: 165-168.
57. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clinics N Am 1993; 77: 185-202.
58. Appadu BL, Strange PG, Lambert DG. Does propofol interact with D2 dopamine receptors? Anesth and Analg 1994; 79: 1191-1192.
59. Hanna JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology 1998; 50: 301-303.